vs
ANI PHARMACEUTICALS INC（ANIP）とPREFORMED LINE PRODUCTS CO（PLPC）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $173.1M、PREFORMED LINE PRODUCTS COの約1.4倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 4.9%、差は6.3%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 3.6%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $11.8M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 10.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
プリフォームド・ライン・プロダクツ社（PLPC）は、送配電、通信、再生可能エネルギーインフラ分野向けのエンジニアリングハードウェアや部品を設計・製造・供給し、世界各国の事業者にネットワークの信頼性と業務効率を高めるソリューションを提供している。
ANIP vs PLPC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $173.1M |
| 純利益 | $27.5M | $8.4M |
| 粗利率 | — | 29.8% |
| 営業利益率 | 14.1% | 6.8% |
| 純利益率 | 11.1% | 4.9% |
| 売上前年比 | 29.6% | 3.6% |
| 純利益前年比 | 367.5% | -19.3% |
| EPS（希薄化後） | $1.14 | $1.72 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $173.1M | ||
| Q3 25 | $227.8M | $178.1M | ||
| Q2 25 | $211.4M | $169.6M | ||
| Q1 25 | $197.1M | $148.5M | ||
| Q4 24 | $190.6M | $167.1M | ||
| Q3 24 | $148.3M | $147.0M | ||
| Q2 24 | $138.0M | $138.7M | ||
| Q1 24 | $137.4M | $140.9M |
| Q4 25 | $27.5M | $8.4M | ||
| Q3 25 | $26.6M | $2.6M | ||
| Q2 25 | $8.5M | $12.7M | ||
| Q1 25 | $15.7M | $11.5M | ||
| Q4 24 | $-10.3M | $10.5M | ||
| Q3 24 | $-24.2M | $7.7M | ||
| Q2 24 | $-2.3M | $9.4M | ||
| Q1 24 | $18.2M | $9.6M |
| Q4 25 | — | 29.8% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | — | 32.7% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 33.3% | ||
| Q3 24 | — | 31.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 31.3% |
| Q4 25 | 14.1% | 6.8% | ||
| Q3 25 | 15.9% | 7.4% | ||
| Q2 25 | 6.6% | 10.1% | ||
| Q1 25 | 13.3% | 8.8% | ||
| Q4 24 | -2.3% | 10.5% | ||
| Q3 24 | -13.8% | 7.1% | ||
| Q2 24 | 3.7% | 8.1% | ||
| Q1 24 | 14.8% | 8.2% |
| Q4 25 | 11.1% | 4.9% | ||
| Q3 25 | 11.7% | 1.5% | ||
| Q2 25 | 4.0% | 7.5% | ||
| Q1 25 | 8.0% | 7.8% | ||
| Q4 24 | -5.4% | 6.3% | ||
| Q3 24 | -16.3% | 5.2% | ||
| Q2 24 | -1.7% | 6.8% | ||
| Q1 24 | 13.2% | 6.8% |
| Q4 25 | $1.14 | $1.72 | ||
| Q3 25 | $1.13 | $0.53 | ||
| Q2 25 | $0.36 | $2.56 | ||
| Q1 25 | $0.69 | $2.33 | ||
| Q4 24 | $-0.45 | $2.13 | ||
| Q3 24 | $-1.27 | $1.54 | ||
| Q2 24 | $-0.14 | $1.89 | ||
| Q1 24 | $0.82 | $1.94 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | — |
| 総負債低いほど良い | — | $38.3M |
| 株主資本純資産 | $540.7M | $475.5M |
| 総資産 | $1.4B | $653.6M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.08× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | — | $55.0M |
| Q4 25 | $540.7M | $475.5M | ||
| Q3 25 | $505.8M | $466.3M | ||
| Q2 25 | $436.8M | $460.7M | ||
| Q1 25 | $418.6M | $435.8M | ||
| Q4 24 | $403.7M | $422.3M | ||
| Q3 24 | $405.9M | $429.0M | ||
| Q2 24 | $455.8M | $416.2M | ||
| Q1 24 | $452.0M | $413.4M |
| Q4 25 | $1.4B | $653.6M | ||
| Q3 25 | $1.4B | $644.6M | ||
| Q2 25 | $1.3B | $631.5M | ||
| Q1 25 | $1.3B | $592.5M | ||
| Q4 24 | $1.3B | $573.9M | ||
| Q3 24 | $1.3B | $592.0M | ||
| Q2 24 | $920.8M | $572.6M | ||
| Q1 24 | $914.5M | $586.1M |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.13× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $21.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $11.8M |
| FCFマージンFCF / 売上 | 11.8% | 6.8% |
| 設備投資強度設備投資 / 売上 | 0.5% | 5.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.60× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $33.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $21.9M | ||
| Q3 25 | $44.1M | $18.9M | ||
| Q2 25 | $75.8M | $26.9M | ||
| Q1 25 | $35.0M | $5.7M | ||
| Q4 24 | $15.9M | $24.1M | ||
| Q3 24 | $12.5M | $9.4M | ||
| Q2 24 | $17.4M | $28.3M | ||
| Q1 24 | $18.3M | $5.8M |
| Q4 25 | $29.1M | $11.8M | ||
| Q3 25 | $38.0M | $8.3M | ||
| Q2 25 | $71.8M | $18.6M | ||
| Q1 25 | $32.5M | $-5.3M | ||
| Q4 24 | $13.5M | $20.6M | ||
| Q3 24 | $7.7M | $5.8M | ||
| Q2 24 | $13.0M | $24.6M | ||
| Q1 24 | $13.7M | $1.8M |
| Q4 25 | 11.8% | 6.8% | ||
| Q3 25 | 16.7% | 4.7% | ||
| Q2 25 | 34.0% | 10.9% | ||
| Q1 25 | 16.5% | -3.6% | ||
| Q4 24 | 7.1% | 12.3% | ||
| Q3 24 | 5.2% | 3.9% | ||
| Q2 24 | 9.4% | 17.7% | ||
| Q1 24 | 10.0% | 1.3% |
| Q4 25 | 0.5% | 5.9% | ||
| Q3 25 | 2.7% | 6.0% | ||
| Q2 25 | 1.9% | 4.9% | ||
| Q1 25 | 1.3% | 7.4% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 3.3% | 2.8% |
| Q4 25 | 1.10× | 2.60× | ||
| Q3 25 | 1.66× | 7.21× | ||
| Q2 25 | 8.87× | 2.12× | ||
| Q1 25 | 2.23× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× | ||
| Q1 24 | 1.00× | 0.60× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PLPC
セグメントデータなし
